In the latest close session, Organon (OGN) was down 3.28% at $8.54. This change lagged the S&P 500's daily gain of 1.02%. On the other hand, the Dow registered a gain of 0.63%, and the technology-centric Nasdaq increased by 1.23%.
Coming into today, shares of the pharmaceutical company had gained 39.06% in the past month. In that same time, the Medical sector lost 4.81%, while the S&P 500 gained 0.63%.
Investors will be eagerly watching for the performance of Organon in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.84, marking a 17.65% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.46 billion, indicating a 3.27% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $6.16 billion, which would represent changes of -7.92% and -0.86%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Organon holds a Zacks Rank of #5 (Strong Sell).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 2.62 right now. This represents a discount compared to its industry average Forward P/E of 15.51.
It's also important to note that OGN currently trades at a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.39 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power , you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Organon & Co. (OGN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).